Limits...
SIP1/NHERF2 enhances estrogen receptor alpha transactivation in breast cancer cells.

Meneses-Morales I, Tecalco-Cruz AC, Barrios-García T, Gómez-Romero V, Trujillo-González I, Reyes-Carmona S, García-Zepeda E, Méndez-Enríquez E, Cervantes-Roldán R, Pérez-Sánchez V, Recillas-Targa F, Mohar-Betancourt A, León-Del-Río A - Nucleic Acids Res. (2014)

Bottom Line: In this study, we have identified the protein Na+/H+ Exchanger RegulatoryFactor 2 (NHERF2) as an ERα-associated coactivator that interacts predominantly with the AF-1 domain of the nuclear receptor.We analyzed the expression of NHERF2 in breast cancer tumors finding a 2- to 17-fold increase in its mRNA levels in 50% of the tumor samples compared to normal breast tissue.These results indicate that NHERF2 is a coactivator of ERα that may participate in the development of estrogen-dependent breast cancer tumors.

View Article: PubMed Central - PubMed

Affiliation: Programa de Investigación de Cáncer de Mama, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, México D.F. 04510, Mexico Departamento de Biología Molecular y Biotecnología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, México D.F. 04510, Mexico.

Show MeSH

Related in: MedlinePlus

NHERF2 mRNA expression in breast cancer tumors. Total RNA was isolated from breast cancer tumor samples and cancer-free mammary tissue obtained during biopsies of 22 patients diagnosed with ERα+ breast cancer. NHERF2 mRNA was amplified by RT- real time quantitative PCR and its relative expression levels were calculated by the 2−ΔΔCT method using β-actin as a reference gene as described in Materials and Methods. NHERF2 mRNA levels in tumor samples were normalized with respect to NHERF2 mRNA levels in normal tissue and represented as mean ± S.E.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4066751&req=5

Figure 6: NHERF2 mRNA expression in breast cancer tumors. Total RNA was isolated from breast cancer tumor samples and cancer-free mammary tissue obtained during biopsies of 22 patients diagnosed with ERα+ breast cancer. NHERF2 mRNA was amplified by RT- real time quantitative PCR and its relative expression levels were calculated by the 2−ΔΔCT method using β-actin as a reference gene as described in Materials and Methods. NHERF2 mRNA levels in tumor samples were normalized with respect to NHERF2 mRNA levels in normal tissue and represented as mean ± S.E.

Mentions: In recent years numerous studies have associated changes in the expression levels of different ERα coregulators with cancer progression, invasiveness, poor prognosis or resistance to hormonal treatment (24–28). In order to explore whether changes in NHERF2 expression could be associated with breast cancer, we determined NHERF2 mRNA expression levels in tumor and cancer-free mammary gland tissue samples from 20 patients diagnosed with stages IIA and IIB of ERα positive breast cancer. Our results showed that in 50% of the breast tumors analyzed (10 patients) NHERF2 mRNA was overexpressed 2- to 17-fold compared to cancer-free tissue mRNA levels (Figure 6). The remaining tumors (10 patients) showed normal or slightly below normal NHERF2 mRNA levels.


SIP1/NHERF2 enhances estrogen receptor alpha transactivation in breast cancer cells.

Meneses-Morales I, Tecalco-Cruz AC, Barrios-García T, Gómez-Romero V, Trujillo-González I, Reyes-Carmona S, García-Zepeda E, Méndez-Enríquez E, Cervantes-Roldán R, Pérez-Sánchez V, Recillas-Targa F, Mohar-Betancourt A, León-Del-Río A - Nucleic Acids Res. (2014)

NHERF2 mRNA expression in breast cancer tumors. Total RNA was isolated from breast cancer tumor samples and cancer-free mammary tissue obtained during biopsies of 22 patients diagnosed with ERα+ breast cancer. NHERF2 mRNA was amplified by RT- real time quantitative PCR and its relative expression levels were calculated by the 2−ΔΔCT method using β-actin as a reference gene as described in Materials and Methods. NHERF2 mRNA levels in tumor samples were normalized with respect to NHERF2 mRNA levels in normal tissue and represented as mean ± S.E.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4066751&req=5

Figure 6: NHERF2 mRNA expression in breast cancer tumors. Total RNA was isolated from breast cancer tumor samples and cancer-free mammary tissue obtained during biopsies of 22 patients diagnosed with ERα+ breast cancer. NHERF2 mRNA was amplified by RT- real time quantitative PCR and its relative expression levels were calculated by the 2−ΔΔCT method using β-actin as a reference gene as described in Materials and Methods. NHERF2 mRNA levels in tumor samples were normalized with respect to NHERF2 mRNA levels in normal tissue and represented as mean ± S.E.
Mentions: In recent years numerous studies have associated changes in the expression levels of different ERα coregulators with cancer progression, invasiveness, poor prognosis or resistance to hormonal treatment (24–28). In order to explore whether changes in NHERF2 expression could be associated with breast cancer, we determined NHERF2 mRNA expression levels in tumor and cancer-free mammary gland tissue samples from 20 patients diagnosed with stages IIA and IIB of ERα positive breast cancer. Our results showed that in 50% of the breast tumors analyzed (10 patients) NHERF2 mRNA was overexpressed 2- to 17-fold compared to cancer-free tissue mRNA levels (Figure 6). The remaining tumors (10 patients) showed normal or slightly below normal NHERF2 mRNA levels.

Bottom Line: In this study, we have identified the protein Na+/H+ Exchanger RegulatoryFactor 2 (NHERF2) as an ERα-associated coactivator that interacts predominantly with the AF-1 domain of the nuclear receptor.We analyzed the expression of NHERF2 in breast cancer tumors finding a 2- to 17-fold increase in its mRNA levels in 50% of the tumor samples compared to normal breast tissue.These results indicate that NHERF2 is a coactivator of ERα that may participate in the development of estrogen-dependent breast cancer tumors.

View Article: PubMed Central - PubMed

Affiliation: Programa de Investigación de Cáncer de Mama, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, México D.F. 04510, Mexico Departamento de Biología Molecular y Biotecnología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, México D.F. 04510, Mexico.

Show MeSH
Related in: MedlinePlus